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INTRODUCTION
Osteoporosis is a concern following allogeneic marrow
and stem cell transplantation [1-4]. Factors potentially
affecting bone metabolism include high-dose chemoradio-
therapy, organ dysfunction, gonadal failure, immunosup-
pressive drugs, weight loss, impaired nutrient intake and
utilization, decreased activity, and altered cytokine function
[5-9]. Total body irradiation may be a risk factor for avascular
necrosis, but its association with development of posttrans-
plantation osteoporosis is unknown [10]. Glucocorticoids
promote development of osteoporosis directly by affecting
bone cells and indirectly by decreasing net calcium absorp-
tion and gonadal hormone synthesis. Glucocorticoids may
alter the structural properties of bone, resulting in a
greater risk of fracture [11,12]. Cyclosporine and tacro-
limus accelerate bone resorption and may decrease gonadal
synthesis [13-15].
The purpose of this prospective study was to determine
whether bone mineral density (BMD) was significantly
altered 3 months following allogeneic transplantation, and if
loss of BMD continued through the ﬁrst year posttransplan-
tation. Findings were correlated with patient and transplan-
tation characteristics to deﬁne risk factors for osteoporosis.
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ABSTRACT
The incidence and course of bone density abnormalities following hematopoietic stem cell transplantation are
poorly understood and complicated by the impact of multiple factors. Hip, spine, and wrist bone mineral densities
(BMDs) were measured in 104 adults (54 women, 54 men; mean age, 40 years [range, 18-64 years]) at 3 and
12 months after allogeneic transplantation. Clinical and laboratory variables were evaluated using univariate and
multivariate analyses to determine risk factors for osteoporosis, fracture, and avascular necrosis. At 3 months
posttransplantation, combined (male and female) hip, spine, and wrist z scores were –0.35, –0.42, and +0.04 stan-
dard deviations, respectively. At 12 months both men and women experienced significant loss of hip BMD (4.2%,
P < .0001); changes in the spine and wrist were minimal. The cumulative dose and number of days of glucocorti-
coid therapy and the number of days of cyclosporine or tacrolimus therapy showed significant associations with
loss of BMD; age, total body irradiation, diagnosis, and donor type did not. Nontraumatic fractures occurred in
10.6% of patients and avascular necrosis in 9.6% within 3 years posttransplantation. The decrease in height
between pretransplantation and 12 months posttransplantation was significant (P = .0001). Results indicate that
loss of BMD after allogeneic stem cell transplantation is common and accelerated by the length of immunosup-
pressive therapy and cumulative dose of glucocorticoid. An increased incidence of fracture and avascular necrosis
may adversely impact long-term quality of life. Prevention of bone demineralization appears warranted after stem
cell transplantation.
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PATIENTS AND METHODS
Patients 18 years and older in hematologic remission
after allogeneic marrow or peripheral stem cell transplanta-
tion for a hematologic malignancy or aplastic anemia were
enrolled 60 to 80 days following transplantation. The Insti-
tutional Review Board of the Fred Hutchinson Cancer
Research Center approved the protocol; each participant
provided informed consent. The study involved measure-
ments of blood parameters and BMD approximately 3 and
12 months posttransplantation.
Biochemical Studies
Blood samples were analyzed for concentrations of crea-
tinine, calcium, phosphorous, magnesium, total bilirubin,
alkaline phosphatase, albumin, follicle stimulating hormone
(FSH), estradiol, and testosterone.
Bone Density Studies
Dominant wrist, right proximal femoral, and lumbar
spine (L1-L4) bone densities were measured 3 and
12 months posttransplantation by dual-energy x-ray
absorptiometry (DEXA) using a Hologic QDR-2000 bone
densitometer, following standard positioning and localizing
procedures. Measurements were concurrent with those in
the Fracture Intervention Trial and followed the same qual-
ity-control measures [16]. The calibration wheel of the
densitometer was replaced during the study; the phantom
values revealed a shift in the baseline of 0.46%, for which
the subject bone density results were adjusted. Duplicate
measurements of total hip BMD in 300 subjects showed a
mean error of 2%.
BMD of subsections of the proximal femur (neck,
trochanter, intertrochanter) was not significantly different
from that of the total hip; thus, only the total hip results are
reported. Hip densities were compared to NHANESIII ref-
erence values for z scores [17]. Spine and wrist densities were
compared to z scores established by Kelly [18]. (A z score of 0
corresponds to the mean BMD for healthy persons matched
by race, age, and sex; a z score of –1 or +1 corresponds to one
standard deviation below or above the normal mean.)
Risk Factors and Fracture Incidence
Factors evaluated for potential influence on BMD are
listed in Table 3. Potential association of BMD with chronic
graft-versus-host disease (GVHD) was not evaluated as a sep-
arate factor because its occurrence and severity were reﬂected
in the length and total dose of glucocorticoid therapy.
The incidence of fracture and avascular necrosis was
determined by radiographic report following a traumatic
event or a patient’s complaint of pain between study entry
and March 1, 1999.
Medications, Diet, and Anthropometry
Women were prescribed cyclical hormone replacement
therapy with medroxyprogesterone (5 mg daily), initiated at
the time of transplantation, and conjugated estrogen (0.625-
1.25 mg daily), initiated 20 to 60 days posttransplantation.
Women who had undergone ovariectomy received estrogen
alone. Compliance with hormone replacement therapy was
ascertained during the 12-month follow-up by the study
coordinator and gynecology nurse practitioner.
All patients were treated with prophylactic intravenous
cyclosporine or tacrolimus, initiated 24 hours pretransplan-
tation. The initial dose of cyclosporine was 3.0 mg/kg daily
(intravenous) and changed to 12.0 mg/kg per day orally as
patients tolerated oral medications. Tacrolimus was initiated
intravenously at 0.03 mg/kg per day and changed to the oral
route as tolerated (0.12 mg/kg per day). Dose adjustments
were based on trough blood concentrations and renal func-
tion. Glucocorticoid therapy was quantiﬁed as the number
of days of treatment and total dose from 10 days before
transplantation to 1 year posttransplantation.
Diagnosis and treatment of acute and chronic GVHD
were conducted as previously reported [19]. Specifically,
patients with acute GVHD received methylprednisolone
(2 mg/kg per day). Patients with chronic GVHD were
treated with alternating-day methylprednisolone (1 mg/kg
per day) and with cyclosporine or tacrolimus.
Diet and supplemental calcium intake was assessed by
one interviewer by dietary recall based on standardized por-
tion sizes and frequency of consumption. The recommended
calcium intake for persons receiving glucocorticoid therapy
was 1500 mg daily; otherwise, 800 mg and 1200 mg was rec-
ommended for men and women, respectively. Frequency and
volume of alcohol consumption were also recorded.
Height was measured without shoes, hats, or wigs, using
a wall-mounted Holtain stadiometer. Weight was measured
to 0.1 kg with light clothing and without shoes.
Statistical Methods
Descriptive statistics for BMD at 3 months posttrans-
plantation were computed separately for men and women.
Subsequent analyses of BMD results were restricted to the
70 individuals who completed both the 3- and 12-month
scans. Means and standard deviations for the 3-month meas-
urements, the follow-up measurements, and the individual
changes in density and z score were computed. Testing for the
statistical signiﬁcance of changes was done using the Wilcoxon
matched-pairs signed rank test. Univariate associations
between continuous covariates and hip z score at 3 months
were assessed using Spearman’s rank correlation coefﬁcient.
For categorical characteristics, statistical testing was con-
ducted with the Wilcoxon rank sum test (2 categories only) or
the Kruskal-Wallis test (3+ categories). Similar analyses
were done for change in hip z score. All P values presented are
2-sided. Exact 95% conﬁdence limits for the median change
in BMD were calculated using a binomial-based method.
RESULTS
Patient Characteristics
Between September 1995 and December 1996, 148 eli-
gible patients were approached for study entry; 105 individ-
uals consented. One patient relapsed before study entry,
leaving 104 for analysis. Seventy patients returned in remis-
sion for analysis at 12 months posttransplantation. Patient
characteristics are provided in Table 1.
Serum Analyses
Median levels of creatinine, calcium, phosphorous, total
bilirubin, alkaline phosphatase, and albumin were normal at
3 and 12 months after transplantation. Frequencies of elevated
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levels at 3 and 12 months, respectively, were creatinine (17, 7),
total bilirubin (15, 8), alkaline phosphatase (0, 4). Low concen-
trations of calcium (2, 1), phosphorous (1, 8), and albumin (35,
11) were found at 3 and 12 months. The median serum mag-
nesium concentration at 3 months was 0.70 mmol/L (range,
0.45-1.10 mmol/L; normal, 0.75-0.98 mmol/L); at 12 months,
the median was 0.80 mmol/L (range, 0.60-1.10 mmol/L).
Bone Density Measurements
Three months posttransplantation. BMD data are pre-
sented in Table 2. Mean hip and lumbar spine z scores were
below 0 in both men and women, with those of women
significantly below those of the normal population (95%
conﬁdence intervals [CI]: hip, –0.67 to –0.17; spine, –0.74 to
–0.10). Associations were found between BMD and percent-
age of ideal body weight, transplantation diagnosis (in par-
ticular acute lymphocytic leukemia, acute myelogenous
leukemia, and myelodysplastic syndrome), and days of glu-
cocorticoid therapy (Table 3).
Change between 3 and 12 months posttransplantation. Both
women and men experienced a signiﬁcant decrease in total
hip BMD between 3 and 12 months posttransplantation
(women: change of –0.035 g/cm2, P = .0007; men: change of
–0.04 g/cm2, P < .0001) (Figure 1). The median percentage
of change was –2.5% (95% CI, –7.3 to –1.0) for women and
–2.4% (95% CI, –3.5 to –1.1) for men. The mean change in
z scores was –0.22 (P = .002; median z score change, –0.24)
for women and –0.28 (P = .0001; median z score change,
–0.22) for men. This loss resulted in 80% of patients at fol-
low-up with hip z scores less than 0, 39% with z scores
below –1.0, and 7% with z scores below –2.0.
We found no significant change in BMD in the wrist
(women, P = .14; men, P = .19) or in the lumbar spine
(women, P = .84; men, P = .22) between 3 and 12 months.
The median percentage of change in spine density was 0.2%
(95% CI, –3.8 to 3.0) in women and –1.7% (95% CI, –2.8
to 1.2) in men. Changes in z scores also were not signiﬁcant
(wrist: women, P = .39; men, P = .40) (lumbar spine: women,
P = .67; men, P = .30). The percentages of wrist and spine
z scores below 0 at 12 months were 54% and 67%, respec-
tively; scores below –1 were 16% and 43%, respectively.
The cumulative dose of glucocorticoid therapy (P =
.006) and the number of days of glucocorticoid therapy (P =
.01) were associated with increasing losses of hip BMD (Fig-
ure 2). The number of days of cyclosporine or tacrolimus
therapy negatively impacted BMD (P = .003) (Table 3). No
association was found for calcium intake, serum testosterone
level, age, total body irradiation, diagnosis, or donor type.
Association between BMD loss and serum estradiol level
was not studied because most women were taking hormone
replacement therapy.
Fracture
Five men and 6 women developed fractures at 4.5 to
36 months posttransplantation, 6 within the ﬁrst year after
transplantation. Fracture sites included 6 vertebra (3 women,
3 men), 2 ankle (2 women), 1 hip (1 woman), 1 pelvis (man),
and 1 rib (man). All patients had received posttransplanta-
tion cyclosporine or tacrolimus therapy (mean, 11.6 months;
range, 6-24 months) and glucocorticoid therapy (mean
length of cumulative treatment, 9.4 months; range, 1-
23 months) before fracture occurred. Five had previous
Table 1. Patient Characteristics*
Enrollment Follow-up Study
(Month 3) (Month 12)
Sex, n
Women 52 31
Men 52 39
Age at enrollment, y
Women, mean (range) 39.7 (18-64) 40.1 (18-64)
Men, mean (range) 40.8 (21-66) 42.1 (23-66)
Disease, n
Aplastic anemia 2 2
Acute lymphocytic leukemia 7 5
Acute myelogenous leukemia 25 13
Chronic myelogenous leukemia 43 33
Myelodysplastic syndrome 13 10
Non-Hodgkin’s lymphoma 8 6
Other 6 1
Allogeneic transplant type, n
Bone marrow 87 57
Peripheral blood 17 13
Donor type, n
HLA-matched sibling donor 51 38
HLA-mismatched related donor 10 5
Unrelated donor 43 27
Disease status at transplantation
Remission/chronic phase 57 44
Relapse/accelerated phase 26 13
Preparative regimen, n
Bu/Cy 27 21
Other chemotherapy 5 4
Cy/TBI 57 38
Bu/TBI 6 0
Other regimens 9 7
Percentage receiving TBI 65 60
Women receiving hormone 51 (98) 28 (90) 
replacement therapy, n (%)
*Bu indicates busulfan; Cy, cyclophosphamide; TBI, total body
irradiation.
Table 2. Bone Density at 3 Months Posttransplantation
Women Men
(n = 52) (n = 52)
Density, g/cm2, mean (SD)
Total hip 0.86 (0.12) 0.98 (0.16)
Lumbar spine 0.96 (0.13) 1.03 (0.17)
Wrist 0.57 (0.04) 0.67 (0.06)
z Score, mean (SD)
Total hip –0.42 (0.91) –0.18 (1.10)
Lumbar spine –0.42 (1.18) –0.37 (1.56)
Wrist 0.28 (0.82) –0.04 (1.11)
Percentage of expected normal 
density, mean (SD)
Total hip 93.9 (13.1) 97.4 (15.3)
Lumbar spine 95.5 (13.1) 96.2 (16.0)
Wrist 102.8 (8.1) 99.7 (8.6)
Percentage with z < –1
Total hip 25% 27%
Lumbar spine 31% 33%
Wrist 6% 25%
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glucocorticoid treatment as part of their chemotherapy regi-
mens. Two of the women with vertebral fractures had not
received hormone replacement therapy. Diagnosis and mean
calcium intakes were not different from those of the entire
study population.
Spine density did not predict fracture rate. Based on the
World Health Organization deﬁnition of osteoporosis [20], only
2 women in the vertebral fracture group had osteoporosis in the
spine at 12 months posttransplantation; of those who developed
fractures at other sites, only 1 woman had osteoporosis.
Avascular Necrosis
Ten patients (7 men, including 2 in the fracture group;
3 women) experienced avascular necrosis at 4 to 28 months
posttransplantation. Sites included the knee, hip, pelvis,
humerus, and femur. Each patient had received cyclo-
sporine or tacrolimus therapy (mean, 11.8 months; range,
4-28 months) and posttransplantation glucocorticoid ther-
apy (mean length of cumulative treatment, 12.9 months;
range, 2-24 months). Six had glucocorticoid exposure
prior to transplantation. Bone density measurements at
Table 3. Association Between Patient Characteristics and Hip Bone Density z Score*
3 Months Posttransplantation 12 Months Posttransplantation
Patient Characteristic Spearman’s Rho† P‡ Spearman’s Rho† P‡
Age –0.07 .48 0.19 .12
Sex — .35 — .85
Percentage of ideal body weight 0.22 .03§ –0.10 .41
Conditioning with TBI — .39 — .80
Disease diagnosis at transplantation — .02§ — .15
AGVHD II-IV — .10 — .52
Days of glucocorticoid therapy –0.19 .05§ –0.30 .01§
Total glucocorticoid dose –0.02 .87 –0.32 .006§
Days of cyclosporine/tacrolimus therapy¶ — — –0.35 .003§
Donor type — .81 — .57
Disease status at BMT (among malignant cases only) — .75 — .06
*TBI indicates total body irradiation; AGVHD, acute graft-versus-host disease; BMT, bone marrow transplantation.
†Computed only for covariates that take on continuous or integer values.
‡For covariates that take on continuous or integer values, the P value presented is from the Spearman rank correlation test. For strictly categori-
cal covariates, the P value comes from a Wilcoxon rank sum test (2 categories only) or a Kruskal-Wallis test (≥3 categories).
§Signiﬁcant association (P ≤ .05).
At the 3-month visit, these categories were deﬁned as ≤40 days (few), 41-60 days (moderate), and >60 days (many). At the follow-up visit, the
categories were <100 days (few), 101-200 days (moderate), and >200 days (many).
¶This factor was not examined at the time of initial dual-energy x-ray absorptiometry scan, because all patients received immunosuppressive
therapy with cyclosporine or tacrolimus for at least the ﬁrst 3 months.
Figure 1. Bone mineral density at 3 and 12 months following allogeneic transplantation. Mean total hip, lumbar spine, and wrist z scores at 3 and
12 months posttransplantation. Data are ± SEM. Asterisks indicate signiﬁcant change; P < .01.
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12 months posttransplantation indicated osteopenia in the
hip and spine in 2 women. Three men had osteopenia in the
hip and 2 had osteopenia in the hip and spine.
Hormonal Function
Twenty-eight of the 31 women who returned for follow-
up were receiving hormone replacement therapy. At
3 months, the median serum FSH level was 0.5 IU/L
(range, 0.4-72 IU/L; normal, 2-22 IU/L; postmenopausal,
20-140 IU/L). Three-month estradiol concentrations were
normal (median, 162 pmol/L; range, <44-426 pmol/L; nor-
mal, 110-1285 pmol/L; postmenopausal, 37-128 pmol/L).
At 12 months, the median FSH level was 37.0 IU/L
(range, 0.4-22 IU/L); 18 of 27 women had postmenopausal
levels. The 12-month median serum estradiol level was
116 pmol/L (range, <44-1189 pmol/L;); 17 of 31 women
had estradiol levels in the postmenopausal range.
Male hormone concentrations were measured at
12 months posttransplantation only. The median serum
testosterone level was 13.6 nmol/L (range, 4.2-36.4 nmol/L;
normal, 10.4-27.7 nmol/L). The median serum FSH con-
centration was 20.5 IU/L (range, 5.9-42 IU/L; normal, 1-
12 IU/L). Six of 37 men had low testosterone concentra-
tions, and 17 of 34 had elevated FSH concentrations
indicating gonadal insufﬁciency.
Height and Weight
A significant loss of height occurred between baseline
and 12 months posttransplantation (mean, –0.47 cm, P =
.0001). Four persons lost more than 1.5 cm; none of these
had documented vertebral compression fractures, nor was
spine BMD consistently diminished. Body weight less than
100% of ideal weight [21] was a risk factor for a lower total
hip z score at 3 months but was not associated with a change
in hip z score between 3 and 12 months.
Diet and Medications
Eighty-eight participants received prophylactic cyclo-
sporine for GVHD; the remaining 16 received tacrolimus.
Of those receiving cyclosporine, 56 completed the study,
including 4 whose therapy was changed to tacrolimus after
study entry due to development of mental status changes,
renal insufﬁciency, or inadequate GVHD control.
Mean calcium intake reported at 12 months was 1367 mg
daily (range, 415-3650 mg); intake was not related to BMD.
Alcohol intake was insigniﬁcant for all individuals.
DISCUSSION
Mean spine density for women 3 months after stem cell
transplantation was signiﬁcantly lower than that of the ref-
erence population; the results for men suggest a risk for
decreased spine BMD. In women, BMD in the hip was
signiﬁcantly lower than that of the reference population; in
men it was not. Clinical factors predicting decreased BMD
included percentage of ideal weight, diagnosis, and days of
glucocorticoid therapy.
Longitudinal follow-up demonstrated a significant
decrease (approximately 2.5% in both sexes) in hip BMD
between 3 and 12 months, but BMD in the spine and wrist
were stable. During the first 3 years after transplantation,
the incidence of symptomatic fractures was 10.6%. Avascu-
lar necrosis was seen in 9.6% of patients.
The length of glucocorticoid therapy was inversely asso-
ciated with the hip z score at 3 months posttransplantation;
total glucocorticoid dose and length of treatment correlated
with a decrease in hip z score between 3 and 12 months
posttransplantation. Bone loss is a recognized complication
of glucocorticoid therapy in doses as low as 7.5 mg daily [5].
Glucocorticoid therapy for acute GVHD can exceed this
threshold dose by a factor of 10 or more, with treatment
lasting 2 or more months. The average duration of treat-
ment of chronic GVHD is 1 to 2 years. Thirty-three per-
cent of HLA-identical sibling–transplant recipients, 49% of
HLA-identical related–transplant recipients, and 64% of
HLA-matched unrelated-donor–transplant recipients
develop clinically extensive chronic GVHD requiring long-
term immunosuppressive therapy with glucocorticoids and
Figure 2. Hip z score at 12 months following allogeneic transplantation. Patients who experienced fractures are denoted as  (male) and 
(female). Note: Not all patients who experienced fractures returned for 12-month studies.
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cyclosporine or tacrolimus [19]. Poor nutrition or reduced
activity could also contribute to bone loss.
Total days of cyclosporine or tacrolimus therapy corre-
lated with loss of BMD. These drugs have been shown to
cause bone loss in transplant recipients, especially at trabec-
ular sites [22-24].
Gonadal dysfunction is an important cause of bone loss
and consequence of stem cell transplantation [25]. Two of
the 3 women who did not take estrogen developed frac-
tures. The abnormal serum FSH and estradiol concentra-
tions in those receiving hormone replacement therapy war-
rant concern. The elevated serum FSH level may have
reﬂected previously suboptimal hormone replacement ther-
apy, because the level may not immediately normalize once
adequate replacement therapy is achieved. More frequent
monitoring and adjustment of hormone therapy based on
laboratory values and clinical symptoms may be necessary
during this early posttransplantation period. Women
should be counseled to avoid taking estrogen and calcium
doses simultaneously to optimize estrogen absorption.
Mode of therapy should be evaluated for persons with mal-
absorption. Men may experience a dose-related reduction
in serum testosterone concentration associated with gluco-
corticoid and cyclosporine therapies [26,27]. Hypogonadal
men given testosterone therapy during glucocorticoid treat-
ment have experienced increased bone mass [28]. Men in
this study did not receive testosterone supplementation;
16% had low serum concentrations at 12 months. Lack of
3-month serum testosterone concentrations prevented cor-
relation between gonadal function and BMD. Early initia-
tion of serial testosterone measurements would allow
timely initiation of replacement therapy, potentially
decreasing bone loss, especially in men destined to receive
prolonged glucocorticoid therapy.
Fractures occurred at higher BMD than predicted from
studies of healthy persons, possibly due to altered bone
architecture associated with glucocorticoid therapy or trans-
plantation-induced alterations in hormones, growth factors,
or cytokines [29]. BMD has also failed to predict fractures
occurring after solid organ transplantation [12,30]. Although
an increased rate of fracture has been associated with local-
ized radiation therapy, we found no effect of total body radi-
ation on posttransplantation bone density [31].
Avascular necrosis is a debilitating transplantation com-
plication associated with glucocorticoid therapy [10,11,32,33].
All patients who developed avascular necrosis had received
glucocorticoid therapy. The 9.6% incidence in our study was
similar to that reported by Weismann et al. and Socie et al. in
stem cell transplantation recipients [32,33].
The association of bone loss with dose and length of
glucocorticoid therapy is consistent with other stem cell
transplantation experiences [2,34]. Contrarily, Kelly et al.
and Kauppila et al. measured signiﬁcant posttransplantation
loss of BMD, but did not ﬁnd glucocorticoid therapy to be
a risk factor [3,35]. Their study populations were small, and
BMD measurements were evaluated as single time values;
in the study by Kauppila et al., measurements were per-
formed later posttransplantation (mean, 3 years). Thus,
results may have been impacted by other variables, includ-
ing lack of estrogen supplementation in the female group in
the study by Kelly et al. or secondary posttransplantation
alterations, including neuroendocrine dysfunction and
muskuloskeletal problems [36].
Ebeling et al. showed an ongoing negative impact of
cyclosporine therapy in patients who received allogeneic
transplants at approximately 30 months posttransplantation
[2]. A study by Valimaki et al. of allogeneic stem cell trans-
plant recipients (95% from HLA-identical siblings) found
reduced BMD prior to transplantation, significant loss of
spine and femoral neck BMD during the first 6 months
posttransplantation (n = 44), but no significant changes
between 6 and 12 months (n = 36) [37]. These results may
have been associated with use of early prophylactic gluco-
corticoid therapy (days 14 through 110 posttransplantation),
few unrelated donor transplants, and delayed hormone
replacement therapy until 6 months posttransplantation.
Kashyap et al. studied 47 patients who received allogeneic
transplants (including 22 with unrelated donors), finding
normal pretransplantation BMD, more rapid loss of BMD
during the ﬁrst 6 months, but ongoing loss through 12 to
14 months after transplantation, more prominent in the hip
[38]. No association was found between glucocorticoid ther-
apy and change in BMD, possibly because the number of
patients who completed the study was small (n = 21) or that
the majority (79%) received prophylactic glucocorticoid
therapy. The loss of BMD beyond 6 months may have been
related to prolonged therapy for GVHD associated with the
larger number of unrelated donors compared with the pop-
ulation in the study by Valimaki et al.
Patients with hematologic malignancies have increased
levels of marrow cytokines, interleukins, and tumor necrosis
factor (TNF), which can stimulate bone resorption. Recov-
ery of marrow function following transplantation and the
associated beneﬁcial effects on cytokine function and levels
of interleukins, TNF, and prostaglandins may attenuate loss
of bone mass following transplantation [29,39].
Our study had some limitations. Lack of pretransplanta-
tion BMD measurements prevented assessment of bone loss
during the ﬁrst 3 months posttransplantation. In the study by
Valimaki et al., 39% of the study population exhibited
osteopenia or osteoporosis before transplantation, possibly
associated with a greater percentage of patients having diag-
noses necessitating pretransplantation treatment than the par-
ticipants in our study and the study by Kashyap et al. [37,38].
The patient group in the study by Ebeling et al., similar to
ours, had normal BMD before allogeneic stem cell transplan-
tation [2]; thus, our low 3-month BMD was possibly a result
of posttransplantation loss. The rate of fracture in our study
may be an underestimation of the true incidence of fracture
because fracture data, based on chart reviews, primarily
reﬂected symptomatic fractures. Spinal radiographs were not
systematically obtained to assess the incidence of potentially
asymptomatic vertebral compression fractures. Bone density
was not measured beyond 12 months posttransplantation,
preventing assessment of direct relationships between BMD
and the occurrence of fractures or avascular necrosis.
Approximately 40% of our patients had z scores below
–1 at 12 months posttransplantation, a level associated with
an increased risk of fracture in large epidemiological studies
(relative risk for a hip fracture = 2.6 for each standard devia-
tion decrease in BMD) [40]. This degree of bone loss fol-
lowing stem cell transplantation, along with the increased
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rate of fracture and avascular necrosis, suggests potential
long-term skeletal complications.
Patients treated for GVHD at this Center have baseline
DEXA scans 3 months after transplantation and are pro-
vided calcium (1500 mg), vitamin D (800 IU), and exercise
guidelines based on those of the National Institutes of
Health, American Association of Rheumatologists, and
National Osteoporosis Foundation [41-43]. Estrogen/
progesterone therapy is prescribed for women unless it is
contraindicated. These measures alone have not proven effec-
tive in preventing osteopenia, osteoporosis, or fractures.
Other interventions are needed. Men should have ear-
lier monitoring of gonadal hormone concentrations, with
appropriate replacement therapy. Bisphosphonate treat-
ment [44]; parathyroid hormone administration, shown to
diminish bone loss during glucocorticoid treatment
[29,45]; anabolic steroids; or selective estrogen receptor
antagonists should be evaluated for safety and efficacy in
the stem cell transplantation population. The efficacy of
therapies should be evaluated by fracture incidence and
prevention in addition to BMD.
In summary, loss of BMD, particularly in the hip, is
common after allogeneic stem cell transplantation. Elevated
fracture rates and development of avascular necrosis have
long-term impacts on quality of life and medical expendi-
tures. The expanding role of transplantation in treating
hematologic, autoimmune, and genetic disorders mandates
further study of the safety and efficacy of pharmacologic
interventions against posttransplantation bone disease.
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